Logo image of PHOE

PHOENIX ASIA HOLDINGS LTD (PHOE) Stock Fundamental Analysis

NASDAQ:PHOE - Nasdaq - KYG7075R1083 - Common Stock - Currency: USD

7.18  +0.09 (+1.27%)

Fundamental Rating

2

Taking everything into account, PHOE scores 2 out of 10 in our fundamental rating. PHOE was compared to 0 industry peers in the Unkown industry. PHOE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PHOE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PHOE had positive earnings in the past year.
In the past year PHOE had a positive cash flow from operations.
PHOE Yearly Net Income VS EBIT VS OCF VS FCFPHOE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 0 200K 400K 600K 800K 1M

1.2 Ratios

Industry RankSector Rank
ROA 23.64%
ROE 38.92%
ROIC 39.38%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PHOE Yearly ROA, ROE, ROICPHOE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 20 40 60

1.3 Margins

Industry RankSector Rank
OM 21.42%
PM (TTM) 18.36%
GM 25.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHOE Yearly Profit, Operating, Gross MarginsPHOE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024 5 10 15 20 25

More info and screens

6

2. Health

2.1 Basic Checks

PHOE has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
PHOE has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, PHOE has an improved debt to assets ratio.
PHOE Yearly Shares OutstandingPHOE Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 5M 10M 15M 20M
PHOE Yearly Total Debt VS Total AssetsPHOE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 1M 2M 3M

2.2 Solvency

PHOE has an Altman-Z score of 55.95. This indicates that PHOE is financially healthy and has little risk of bankruptcy at the moment.
PHOE has a debt to FCF ratio of 0.04. This is a very positive value and a sign of high solvency as it would only need 0.04 years to pay back of all of its debts.
A Debt/Equity ratio of 0.01 indicates that PHOE is not too dependend on debt financing.
Even though the debt/equity ratio score it not favorable for PHOE, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.04
Altman-Z 55.95
ROIC/WACC3.92
WACC10.04%
PHOE Yearly LT Debt VS Equity VS FCFPHOE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 0 500K 1M 1.5M

2.3 Liquidity

A Current Ratio of 2.37 indicates that PHOE has no problem at all paying its short term obligations.
PHOE has a Quick Ratio of 2.37. This indicates that PHOE is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.37
Quick Ratio 2.37
PHOE Yearly Current Assets VS Current LiabilitesPHOE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2023 2024 1M 2M 3M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 200.00% over the past year.
The Revenue has grown by 158.27% in the past year. This is a very strong growth!
EPS 1Y (TTM)200%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.19%
Revenue 1Y (TTM)158.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%26.93%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PHOE Yearly Revenue VS EstimatesPHOE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 1M 2M 3M 4M 5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 143.60, PHOE can be considered very expensive at the moment.
PHOE's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.93.
Industry RankSector Rank
PE 143.6
Fwd PE N/A
PHOE Price Earnings VS Forward Price EarningsPHOE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 261.44
EV/EBITDA 118.34
PHOE Per share dataPHOE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.05 0.1 0.15 0.2 0.25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PHOE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHOENIX ASIA HOLDINGS LTD

NASDAQ:PHOE (8/15/2025, 10:07:15 AM)

7.18

+0.09 (+1.27%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners74.54%
Ins Owner ChangeN/A
Market Cap155.09M
AnalystsN/A
Price TargetN/A
Short Float %0.59%
Short Ratio0.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 143.6
Fwd PE N/A
P/S 26.95
P/FCF 261.44
P/OCF 259.47
P/B 57.12
P/tB 57.12
EV/EBITDA 118.34
EPS(TTM)0.05
EY0.7%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.03
FCFY0.38%
OCF(TTM)0.03
OCFY0.39%
SpS0.27
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 23.64%
ROE 38.92%
ROCE 45.06%
ROIC 39.38%
ROICexc 100.37%
ROICexgc 100.37%
OM 21.42%
PM (TTM) 18.36%
GM 25.79%
FCFM 10.31%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.04
Debt/EBITDA 0.01
Cap/Depr 9.68%
Cap/Sales 0.08%
Interest Coverage 1761
Cash Conversion 46.69%
Profit Quality 56.14%
Current Ratio 2.37
Quick Ratio 2.37
Altman-Z 55.95
F-ScoreN/A
WACC10.04%
ROIC/WACC3.92
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)200%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.19%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)158.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%26.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y227.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y777.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1046.23%
OCF growth 3YN/A
OCF growth 5YN/A